ALIM: Alimera Sciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 185.33
Enterprise Value ($M) 237.77
Book Value ($M) 46.17
Book Value / Share 0.88
Price / Book 4.01
NCAV ($M) -54.93
NCAV / Share -1.05
Price / NCAV -3.37

Profitability (mra)
Return on Invested Capital (ROIC) -0.18
Return on Assets (ROA) -0.42
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 2.31
Current Ratio 2.39

Balance Sheet (mrq) ($M)
Current Assets 52.42
Assets 153.52
Liabilities 107.36
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 80.75
Operating Income -1.93
Net Income -20.13
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -14.26
Cash from Investing -75.53
Cash from Financing 96.50

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Lytton Laurence W 4.20 -26.78
02-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 0.90 0.00
02-13 13G/A Stonepine Capital Management, LLC 9.99 -0.07
02-13 13G/A Altium Capital Management LP 5.00 -10.88
02-13 13G/A Boothbay Fund Management, Llc 6.10 -33.14
12-08 13G/A Morgan Stanley 1.80 37.52
08-16 13D/A Velan Capital Investment Management LP 26.00 0.00
08-03 13D/A Caligan Partners LP 33.10 -100.00
2023-04-03 13G/A Palo Alto Investors LP 0.00 -100.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPO
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PU
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT P
2023-05-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-16 3,615 47,439 7.62
2024-04-15 6,208 34,306 18.10
2024-04-12 11,327 15,606 72.58
2024-04-11 3,644 10,650 34.22

(click for more detail)

Similar Companies
ACIU – AC Immune SA ACRV – Acrivon Therapeutics, Inc.
ADMA – ADMA Biologics, Inc. ALPN – Alpine Immune Sciences, Inc.
ALT – Altimmune, Inc.


Financial data and stock pages provided by
Fintel.io


Finpedia: Almira Sciences